CordenPharma Colorado Partners with BioMed Realty on Peptide Development Lab Expansion

CordenPharma Colorado is partnering with BioMed Realty to expand its peptide development capabilities in Boulder with the lease of a 64,000-sf facility in Flatiron Park. Located near the CDMO’s large-scale peptide manufacturing hub, the state-of-the-art building will accommodate process development and analytical services, enabling seamless integration of advanced peptide API (Active Pharmaceutical Ingredient) creation from production to commercialization. OZ Architecture designed the two-story structure to support complex scientific operations with adaptable lab grids, robust power capacity, vibration mitigation, efficient waste disposal, and advanced mechanical and utility systems.

Certified LEED Gold, the robust and sustainable facility incorporates rooftop photovoltaic arrays and is clad in a custom metal panel skin. An iconic glazed exterior stair provides access to an outdoor plaza and the lower parking level, with an amenity deck supplying a range of settings for informal exchange. Delivered by Calcon Constructors, 5505 Central Avenue will be occupied solely by CordenPharma for a lease term of 15 years.

Featuring highly resilient infrastructure, Flatiron Park offers a connected campus experience with curated amenities such as an onsite gym and numerous restaurants. A tenant-first operating model empowers companies to advance their corporate missions and focus on innovation and strategic growth. Spanning 1,131,000 sf of life sciences, biomanufacturing, and best-in-class office space, the 24-building property is situated in a well-established ecosystem with optimal proximity to universities, research institutions, and leading venture capital firms, plus access to one of the most educated workforces in the country. Flatiron Park was acquired by BioMed Realty from Crescent Real Estate for $625 million in April of 2022. The transaction represents the largest single-asset sale in Colorado’s history.